Your browser doesn't support javascript.
loading
European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Européenne des Médecins Spécialistes).
Kandolf, Lidija; Peris, Ketty; Malvehy, Josep; Mosterd, Klara; Heppt, Markus V; Fargnoli, Maria Concetta; Berking, Carola; Arenberger, Petr; Bylaite-Bucinskiene, Matilda; Del Marmol, Veronique; Dirschka, Thomas; Dreno, Brigitte; Forsea, Ana-Maria; Harwood, Catherine A; Hauschild, Axel; Heerfordt, Ida Marie; Kauffman, Roland; Kelleners-Smeets, Nicole; Lallas, Aimilios; Lebbe, Celeste; Leiter, Ulrike; Longo, Caterina; Mijuskovic, Zeljko; Pellacani, Giovanni; Puig, Susana; Saiag, Philippe; Situm, Mirna; Stockfleth, Eggert; Salavastru, Carmen; Stratigos, Alexander; Zalaudek, Iris; Garbe, Claus.
Afiliação
  • Kandolf L; Department of Dermatology, Faculty of Medicine, University of Defence, Military Medical Academy, Belgrade, Serbia.
  • Peris K; UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endrocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
  • Malvehy J; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Mosterd K; Dermatology Department of Hospital Clinic of Barcelona, IDIBAPS, CIBER de Enfermedades Raras, Instituto Carlos III, University of Barcelona, Barcelona, Spain.
  • Heppt MV; Department of Dermatology, Maastricht University Medical Centre+ Comprehensive Cancer Centre, Maastricht, The Netherlands.
  • Fargnoli MC; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Berking C; Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Arenberger P; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CC ER-EMN), Erlangen, Germany.
  • Bylaite-Bucinskiene M; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Del Marmol V; Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Dirschka T; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CC ER-EMN), Erlangen, Germany.
  • Dreno B; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
  • Forsea AM; Clinic of Infectious Diseases and Dermatovenereology, Centre of Dermatovenereology, Vilnius University, Vilnius, Lithuania.
  • Harwood CA; Department of Dermatology, University Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
  • Hauschild A; Faculty of Health, University Witten-Herdecke, Witten, Germany.
  • Heerfordt IM; CentroDerm Clinic, Wuppertal, Germany.
  • Kauffman R; Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France.
  • Kelleners-Smeets N; Department of Oncologic Dermatology, Elias University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Lallas A; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Lebbe C; Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • Leiter U; Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Longo C; Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany.
  • Mijuskovic Z; Department of Dermatology, Maastricht University Medical Centre+ Comprehensive Cancer Centre, Maastricht, The Netherlands.
  • Pellacani G; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
  • Puig S; First Department of Dermatology, Aristotle University, Thessaloniki, Greece.
  • Saiag P; Université Paris Cite, AP-HP Dermato-oncology, Cancer institute APHP, Nord Paris cité, INSERM U976, Saint Louis Hospital, Paris, France.
  • Situm M; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
  • Stockfleth E; Skin Cancer Center, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Salavastru C; Department of Dermatology, Faculty of Medicine, University of Defence, Military Medical Academy, Belgrade, Serbia.
  • Stratigos A; Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
  • Zalaudek I; Dermatology Department of Hospital Clinic of Barcelona, IDIBAPS, CIBER de Enfermedades Raras, Instituto Carlos III, University of Barcelona, Barcelona, Spain.
  • Garbe C; Department of General and Oncologic Dermatology, Ambroise Paré Hospital, APHP, & EA 4340 "Biomarkers in Cancerology and Hemato-Oncology", UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.
J Eur Acad Dermatol Venereol ; 38(6): 1024-1047, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38451047
ABSTRACT
A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology, the European Dermatology Forum, the European Academy of Dermatology and Venereology, and the European Union of Medical Specialists was formed to develop European recommendations on AK diagnosis and treatment, based on current literature and expert consensus. This guideline addresses the epidemiology, diagnostics, risk stratification and treatments in immunocompetent as well as immunosuppressed patients. Actinic keratoses (AK) are potential precursors of cutaneous squamous cell carcinoma (cSCC) and display typical histopathologic and immunohistochemical features of this malignancy in an early stage. They can develop into cSSC in situ and become invasive in a low percentage of cases. AK is the most frequent neoplasia in white populations, frequently occurring within a cancerous field induced by ultraviolet radiation. Since it cannot be predicted, which lesion will progress to cSCC and when treatment is usually recommended. The diagnosis of AK and field cancerization is made by clinical examination. Dermatoscopy, confocal microscopy, optical coherence tomography or line-field confocal-OCT can help in the differential diagnosis of AK and other skin neoplasms. A biopsy is indicated in clinically and/or dermatoscopically suspicious and/or treatment-refractory lesions. The choice of treatment depends on patients' and lesion characteristics. For single non-hyperkeratotic lesions, the treatment can be started upon patient's request with destructive treatments or topical treatments. For multiple lesions, field cancerization treatment is advised with topical treatments and photodynamic therapy. Preventive measures such as sun protection, self-examination and repeated field cancerization treatments of previously affected skin areas in high-risk patients are advised.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ceratose Actínica Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ceratose Actínica Limite: Humans País/Região como assunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article